Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease

American Diabetes Association, 2003, Management of dyslipidemia in adults with diabetes, Diabetes Care, 26, S83, 10.2337/diacare.26.7.2194 Ansell, 2005, High-density lipoprotein function recent advances, J Am Coll Cardiol, 46, 1792, 10.1016/j.jacc.2005.06.080 Ashen, 2005, Clinical practice. Low HDL cholesterol levels, N Engl J Med, 353, 1252, 10.1056/NEJMcp044370 Assmann, 1993, High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations, Circulation, 87, III28 Assmann, 1996, High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport, Atherosclerosis, 124, S11, 10.1016/0021-9150(96)05852-2 Assmann, 2004, HDL cholesterol and protective factors in atherosclerosis, Circulation, 109, III8, 10.1161/01.CIR.0000131512.50667.46 Asztalos, 2000, Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease, Arterioscler Thromb Vasc Biol, 20, 2670, 10.1161/01.ATV.20.12.2670 Asztalos, 2004, High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study, Arterioscler Thromb Vasc Biol, 24, 2181, 10.1161/01.ATV.0000146325.93749.a8 Asztalos, 2005, Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux, J Lipid Res, 46, 2246, 10.1194/jlr.M500187-JLR200 Ballantyne, 1999, Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy, Circulation, 99, 736, 10.1161/01.CIR.99.6.736 Ballantyne, 2001, Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S, Circulation, 104, 3046, 10.1161/hc5001.100624 Barzilai, 2003, Unique lipoprotein phenotype and genotype associated with exceptional longevity, Jama, 290, 2030, 10.1001/jama.290.15.2030 Barter, 2002, Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells, Curr Opin Lipidol, 13, 285, 10.1097/00041433-200206000-00008 Barter, 2001, Cholesteryl ester transfer protein, high density lipoprotein and arterial disease, Curr Opin Lipidol, 12, 377, 10.1097/00041433-200108000-00002 Barter, 2003, Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis, Arterioscler Thromb Vasc Biol, 23, 160, 10.1161/01.ATV.0000054658.91146.64 Barter, 2004, Antiinflammatory properties of HDL, Circ Res, 95, 764, 10.1161/01.RES.0000146094.59640.13 Birjmohun, 2005, Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials, J Am Coll Cardiol, 45, 185, 10.1016/j.jacc.2004.10.031 Blanche, 1981, Characterization of human high-density lipoproteins by gradient gel electrophoresis, Biochim Biophys Acta, 665, 408, 10.1016/0005-2760(81)90253-8 Bots, 2005, Design of a study on the effect of Torcetrapib/Atorvastatin versus Atorvastatin alone on carotid intima-media thickness in patients with mixed Hyperlipidemia [poster] Brewer, 2003, Benefit-risk assessment of Rosuvastatin 10 to 40milligrams, Am J Cardiol, 92, 23K, 10.1016/S0002-9149(03)00779-3 Brewer, 2004, Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease, Arterioscler Thromb Vasc Biol, 24, 1755, 10.1161/01.ATV.0000142804.27420.5b Brousseau, 2004, Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol, N Engl J Med, 350, 1505, 10.1056/NEJMoa031766 Brown, 2001, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, N Engl J Med, 345, 1583, 10.1056/NEJMoa011090 Bowry, 1992, High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors, Proc Natl Acad Sci U S A, 89, 10316, 10.1073/pnas.89.21.10316 Calabresi, 2003, Endothelial protection by high-density lipoproteins: from bench to bedside, Arterioscler Thromb Vasc Biol, 23, 1724, 10.1161/01.ATV.0000094961.74697.54 Calabresi, 1994, Molecular characterization of native and recombinant apolipoprotein A-IMilano dimer. The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein A-I, J Biol Chem, 269, 32168, 10.1016/S0021-9258(18)31616-8 Canner, 1986, Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin, J Am Coll Cardiol, 8, 1245, 10.1016/S0735-1097(86)80293-5 Capuzzi, 2003, Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels, Am J Cardiol, 91, 1304, 10.1016/S0002-9149(03)00318-7 Carlson, 1962, The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis, Acta Med Scand, 172, 641, 10.1111/j.0954-6820.1962.tb07203.x Castelli, 1986, Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study, Jama, 256, 2835, 10.1001/jama.256.20.2835 Chapman, 2003, Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives, Atherosclerosis, 171, 1, 10.1016/S0021-9150(03)00156-4 Chapman, 1981, A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum, J Lipid Res, 22, 339, 10.1016/S0022-2275(20)35376-1 Chapman, 2004, Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid—a position paper developed by the European Consensus Panel on HDL-C, Curr Med Res Opin, 20, 1253, 10.1185/030079904125004402 Clark, 2004, Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib, Arterioscler Thromb Vasc Biol, 24, 490, 10.1161/01.ATV.0000118278.21719.17 Clark, 2006, Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action, J Lip Res, 47, 537, 10.1194/jlr.M500349-JLR200 Cockerill, 2001, Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation, Circulation, 103, 108, 10.1161/01.CIR.103.1.108 Dachet, 2000, New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation, Arterioscler Thromb Vasc Biol, 20, 507, 10.1161/01.ATV.20.2.507 Davidson, 2005, Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor torcetrapib when administered with and without atorvastatin to subjects with a low level of high-density lipoprotein cholesterol, Presented at the Annual Scientific Session of the American College of Cardiology, Orlando, Florida, 802 De Backer, 2003, European guidelines on cardiovascular disease prevention in clinical practice. Executive Summary. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice, Eur Heart J, 24, 1601, 10.1016/S0195-668X(03)00347-6 Decossin, 1995, Prevention of in vitro low-density lipoprotein oxidation by an albumin-containing Lp A-I subfraction, Biochim Biophys Acta, 1255, 31, 10.1016/0005-2760(94)00213-I de Grooth, 2002, Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study, Circulation, 105, 2159, 10.1161/01.CIR.0000015857.31889.7B Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, Lancet., 366, 1279, 10.1016/S0140-6736(05)67528-9 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study., JAMA, 279, 1615, 10.1001/jama.279.20.1615 2001, Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study, Lancet, 357, 905, 10.1016/S0140-6736(00)04209-4 Epand, 1994, HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity, Arterioscler Thromb, 14, 1775, 10.1161/01.ATV.14.11.1775 Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III); 2001. Fagerberg, 2005, Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population, Diabetologia, 48, 1716, 10.1007/s00125-005-1846-8 Fleisher, 1982, Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins, J Biol Chem, 257, 6653, 10.1016/S0021-9258(18)34477-6 Franceschini, 1999, Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice, Arterioscler Thromb Vasc Biol, 19, 1257, 10.1161/01.ATV.19.5.1257 Frick, 1987, Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease, N Engl J Med, 317, 1237, 10.1056/NEJM198711123172001 Fruchart, 2001, The role of fibric acids in atherosclerosis, Curr Atheroscler Rep, 3, 83, 10.1007/s11883-001-0015-x Genest, 1992, Familial lipoprotein disorders in patients with premature coronary artery disease, Circulation, 85, 2025, 10.1161/01.CIR.85.6.2025 Gotto, 2004, Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update, J Am Coll Cardiol, 43, 717, 10.1016/j.jacc.2003.08.061 Gordon, 1977, High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study, Am J Med, 62, 707, 10.1016/0002-9343(77)90874-9 Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies, Circulation, 79, 8, 10.1161/01.CIR.79.1.8 Goulinet, 1997, Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis, Arterioscler Thromb Vasc Biol, 17, 786, 10.1161/01.ATV.17.4.786 Guerin, 2001, Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia, Arterioscler Thromb Vasc Biol, 21, 282, 10.1161/01.ATV.21.2.282 Guyton, 1998, Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia, Am J Cardiol, 82, 737, 10.1016/S0002-9149(98)00448-2 Haffner, 2004, Dyslipidemia management in adults with diabetes, Diabetes Care, 27, S68 Hajduk, 1989, Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein, J Biol Chem, 264, 5210, 10.1016/S0021-9258(18)83720-6 Hannuksela, 1992, Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol, J Lipid Res, 33, 737, 10.1016/S0022-2275(20)41437-3 Hansel, 2004, Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity, J Clin Endocrinol Metab, 89, 4963, 10.1210/jc.2004-0305 Huang, 2002, Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia, Clin Sci (Lond), 103, 587, 10.1042/cs1030587 International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf. Accessed October 16, 2005. Jin, 1997, Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport, Arterioscler Thromb Vasc Biol, 17, 2020, 10.1161/01.ATV.17.10.2020 Ji, 1999, Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile, J Biol Chem, 274, 33398, 10.1074/jbc.274.47.33398 Karpe, 2004, The nicotinic acid receptor-a new mechanism for an old drug, Lancet, 363, 1892, 10.1016/S0140-6736(04)16359-9 Kashyap, 2002, Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia, Am J Cardiol, 89, 672, 10.1016/S0002-9149(01)02338-4 Kastelein, 2005, Design of a study comparing Torcetrapib/Atorvastatin with Atorvastatin alone on carotid atherosclerosis in patients with familial Hypercholesterolemia Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2 Kimura, 2001, Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells, J Biol Chem, 276, 31780, 10.1074/jbc.M104353200 Khovidhunkit, 2004, Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host, J Lipid Res, 45, 1169, 10.1194/jlr.R300019-JLR200 Knoblauch, 2004, Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol, Hum Mol Genet, 13, 993, 10.1093/hmg/ddh119 Kontush, 2003, Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress, Arterioscler Thromb Vasc Biol, 23, 1881, 10.1161/01.ATV.0000091338.93223.E8 Kozyraki, 2001, Cubilin, a multifunctional epithelial receptor: an overview, J Mol Med, 79, 161, 10.1007/s001090100193 Kuivenhoven, 2004, Inhibition of cholesteryl ester transfer protein by JJT-705 in combination with pravastatin in type II dyslipidemia LaRosa, 2005, Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, 1425, 10.1056/NEJMoa050461 Lawn, 1999, The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway, J Clin Invest, 104, R25, 10.1172/JCI8119 Le Goff, 2004, Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia, Pharmacol Ther, 101, 17, 10.1016/j.pharmthera.2003.10.001 Lewis, 2005, New insights into the regulation of HDL metabolism and reverse cholesterol transport, Circ Res, 96, 1221, 10.1161/01.RES.0000170946.56981.5c Libby, 2002, Inflammation and atherosclerosis, Circulation, 105, 1135, 10.1161/hc0902.104353 Ljung, 2002, AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats, J Lipid Res, 43, 1855, 10.1194/jlr.M200127-JLR200 Mackness, 2000, How high-density lipoprotein protects against the effects of lipid peroxidation, Curr Opin Lipidol, 11, 383, 10.1097/00041433-200008000-00007 Mackness, 2003, Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study, Circulation, 107, 2775, 10.1161/01.CIR.0000070954.00271.13 Mackness, 2004, Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells, Biochem Biophys Res Commun, 318, 680, 10.1016/j.bbrc.2004.04.056 Maeda, 2003, The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis, Prev Med, 37, 283, 10.1016/S0091-7435(03)00110-5 Mineo, 2003, High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases, J Biol Chem, 278, 9142, 10.1074/jbc.M211394200 Miyazaki, 2001, Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone, Diabetes Care, 24, 710, 10.2337/diacare.24.4.710 Morehouse, 2004, The CETP-inhibitor torcetrapib raises HDL and prevents aortic atherosclerosis in rabbits Mosca, 2004, Evidence-based guidelines for cardiovascular disease prevention in women, Circulation, 109, 672, 10.1161/01.CIR.0000114834.85476.81 Navab, 1991, Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein, J Clin Invest, 88, 2039, 10.1172/JCI115532 Navab, 2000, Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3, J Lipid Res, 41, 1495, 10.1016/S0022-2275(20)33462-3 Navab, 2001, HDL and the inflammatory response induced by LDL-derived oxidized phospholipids, Arterioscler Thromb Vasc Biol, 21, 481, 10.1161/01.ATV.21.4.481 Navab, 2005, Apolipoprotein A-I mimetic peptides, Arterioscler Thromb Vasc Biol, 25, 1325, 10.1161/01.ATV.0000165694.39518.95 Nicholls, 2005, Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits, Circulation, 111, 1543, 10.1161/01.CIR.0000159351.95399.50 Nicholls, 2005, Formation of dysfunctional high-density lipoprotein by myeloperoxidase, Trends Cardiovasc Med, 15, 212, 10.1016/j.tcm.2005.06.004 Nissen, 2003, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial, JAMA, 290, 2292, 10.1001/jama.290.17.2292 Nissen, 2005, Design of a study comparing Torcetrapib/Atorvastatin with atorvastatin alone on Atheroma volume in patients with coronary heart disease [poster] Nobecourt, 2005, Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia, Diabetologia, 48, 529, 10.1007/s00125-004-1655-5 Nofer, 2001, Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids, J Biol Chem, 276, 34480, 10.1074/jbc.M103782200 Nofer, 2004, HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3, J Clin Invest, 113, 569, 10.1172/JCI200418004 Ohara, 1993, Hypercholesterolemia increases endothelial superoxide anion production, J Clin Invest, 91, 2546, 10.1172/JCI116491 Okamoto, 2000, A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits, Nature, 406, 203, 10.1038/35018119 Oliver, 2001, A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport, Proc Natl Acad Sci U S A, 98, 5306, 10.1073/pnas.091021198 Rader, 2000, The endothelium and lipoproteins: insights from recent cell biology and animal studies, Semin Thromb Hemost, 26, 521, 10.1055/s-2000-13208 Raskin, 2001, A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes, Diabetes Care, 24, 1226, 10.2337/diacare.24.7.1226 Reddy, 2006, Oral amphipathic peptides as therapeutic agents, Expert Opin Investig Drugs, 15, 13, 10.1517/13543784.15.1.13 Robins, 2001, Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial, JAMA, 285, 1585, 10.1001/jama.285.12.1585 Ross, 1999, Atherosclerosis-an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207 Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604 Rubic, 2004, Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin, Biochem Pharmacol, 67, 411, 10.1016/j.bcp.2003.09.014 Sacks, 2002, The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations, Am J Cardiol, 90, 139, 10.1016/S0002-9149(02)02436-0 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N Engl J, 335, 1001, 10.1056/NEJM199610033351401 Schaefer, 1999, Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease, Atherosclerosis, 144, 177, 10.1016/S0021-9150(99)00053-2 Schwartz, 2004, Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans, J Lipid Res, 45, 1594, 10.1194/jlr.M300511-JLR200 Sharrett, 2001, Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study, Circulation, 104, 1108, 10.1161/hc3501.095214 Shepherd, 1979, Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism, J Clin Invest, 63, 858, 10.1172/JCI109385 Shih, 1996, Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model, J Clin Invest, 97, 1630, 10.1172/JCI118589 Shih, 1998, Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis, Nature, 394, 284, 10.1038/28406 Spate-Douglas, 1999, Exercise intensity: its effect on the high-density lipoprotein profile, Arch Phys Med Rehabil, 80, 691, 10.1016/S0003-9993(99)90174-0 Spiegelman, 1998, PPAR-gamma: adipogenic regulator and thiazolidinedione receptor, Diabetes, 47, 507, 10.2337/diabetes.47.4.507 Spieker, 2002, High-density lipoprotein restores endothelial function in hypercholesterolemic men, Circulation, 105, 1399, 10.1161/01.CIR.0000013424.28206.8F Sprecher, 2004, HDL-C effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist 2005, Standards of medical care in diabetes, Diabetes Care, 28, S4, 10.2337/diacare.28.suppl_1.S4 Sugatani, 1996, High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells, J Lipid Mediat Cell Signal, 13, 73, 10.1016/0929-7855(95)00047-X 1993, Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II), JAMA, 269, 3015, 10.1001/jama.269.23.3015 Tall, 1993, Plasma cholesteryl ester transfer protein, J Lipid Res, 34, 1255, 10.1016/S0022-2275(20)36957-1 Taylor, 2004, Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins, Circulation, 110, 3512, 10.1161/01.CIR.0000148955.19792.8D The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 Therond, 1999, Copper oxidation of in vitro dioleolylphosphatidylcholine-enriched high-density lipoproteins: physicochemical features and cholesterol effluxing capacity, Arch Biochem Biophys, 362, 139, 10.1006/abbi.1998.0997 The Scandinavian Simvastatin Survival Study Group, 1995, Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S), Lancet, 345, 1274, 10.1016/S0140-6736(95)90926-5 Thompson, 2004, Therapeutic approaches to raising plasma HDL-cholesterol levels, Nat Clin Pract, 1, 84, 10.1038/ncpcardio0044 Toth, 2003, Reverse cholesterol transport: high-density lipoprotein's magnificent mile, Curr Atheroscler Rep, 5, 386, 10.1007/s11883-003-0010-5 Ulevitch, 1979, New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides, J Clin Invest, 64, 1516, 10.1172/JCI109610 Vakkilainen, 2003, Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS), Circulation, 107, 1733, 10.1161/01.CIR.0000057982.50167.6E Viswambharan, 2004, Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase, Circ Res, 94, 918, 10.1161/01.RES.0000124302.20396.B7 Wallace, 2005, Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys, J Lipid Res, 46, 1009, 10.1194/jlr.M500002-JLR200 Wang, 2004, HDL: the metabolism, function, and therapeutic importance, Chem Rev, 104, 119, 10.1021/cr020466v Wang, 2004, ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins, Proc Natl Acad Sci U S A, 101, 9774, 10.1073/pnas.0403506101 Weissberg, 2000, Atherogenesis: current understanding of the causes of atheroma, Heart, 83, 247, 10.1136/heart.83.2.247 Whitney, 2005, A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events, Ann Intern Med, 142, 95, 10.7326/0003-4819-142-2-200501180-00008 Williams, 1999, Scavenger receptor BI and cholesterol trafficking, Curr Opin Lipidol, 10, 329, 10.1097/00041433-199908000-00007 Wilsgaard, 2004, Change in serum lipids and body mass index by age, sex, and smoking status: the Tromso study 1986–1995, Ann Epidemiol, 14, 265, 10.1016/j.annepidem.2003.08.004 Wolfe, 2001, Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia, Am J Cardiol, 87, 10.1016/S0002-9149(00)01410-7 Yancey, 2003, Importance of different pathways of cellular cholesterol efflux, Arterioscler Thromb Vasc Biol, 23, 712, 10.1161/01.ATV.0000057572.97137.DD Young, 1994, Why are low-density lipoproteins atherogenic?, West J Med, 160, 153 Yuhanna, 2001, High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase, Nat Med, 7, 853, 10.1038/89986 Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9 Zhang, 2003, Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo, Circulation, 108, 661, 10.1161/01.CIR.0000086981.09834.E0